Thursday, September 8, 2022 Daily Archives

Lonza boosts mRNA services through Touchlight collaboration

The partnership will see CDMO Lonza integrate Touchlight’s doggybone DNA tech into its messenger RNA (mRNA) manufacturing offering. Swiss contract development and manufacturing organization (CDMO) Lonza has been at the forefront of mRNA production, in part due to major contracts to supply the drug substance for hundreds of millions of doses of Moderna’s COVID-19 vaccine, Spikevax. It’s oligonucleotide and RNA production capabilities have also been bolstered through various investments across its global network, including an expansion at its Visp, Switzerland…

Avid points at mammalian and CGT expansions for drop in margins

Avid Bioservices says mammalian expansions and a move into the cell and gene therapy space has put pressure on its margins, which fell 12% in the first quarter of fiscal 2023. For the first quarter FY2023, Avid reported revenues of $36.7 million, a 19% increase compared to the $30.8 million recorded the previous year. However, despite CEO of Avid, Nick Green stating that this is the contract development manufacturing organization’s (CDMO’s) highest quarterly revenue on record, the firm’s margins fell…